Form 4: MAIA Director Stan Smith Boosts Stake with Stock, Options

MAIA Biotechnology Director Stan Smith acquired 57,189 shares of common stock and 57,189 stock options, signaling increased insider confidence.

Summary

• Stan Smith, a Director of MAIA Biotechnology, Inc. (MAIA), reported transactions on December 22, 2025.
• He purchased 57,189 shares of Common Stock at a price of $1.224 per share.
• He also acquired 57,189 stock options (deemed warrants) with an exercise price of $1.36 per share.
• The common stock and options were purchased pursuant to a Securities Purchase Agreement and issued under the Issuer's 2021 Equity Incentive Plan.
• Following these transactions, Mr. Smith beneficially owns 1,421,478 shares of common stock indirectly through The Stan V. Smith Trust Dated 1993.
• He also indirectly owns 4,580 shares each through three family trusts (Blake Sarai Teitei Smith IL Unif Trns Min Act, Gage Quentin Smith IL Unif Trns Min Act, Travis Deo Zai Zai Smith IL Unif Trns Min Act), disclaiming beneficial ownership except for his pecuniary interest.
• He indirectly owns 57,189 stock options through The Stan V. Smith Trust Dated 1993, which will be exercisable from June 22, 2026, and expire on December 22, 2028.

Sentiment

Score: 7

Explanation: The director's purchase of additional shares and options indicates a positive outlook and confidence in the company's future, which is generally a bullish signal for investors.

Positives

• A company director, Stan Smith, increased his beneficial ownership in MAIA Biotechnology, Inc. through the purchase of common stock and stock options.
• The acquisition of 57,189 shares of common stock at $1.224 per share and 57,189 stock options at an exercise price of $1.36 per share indicates management's confidence in the company's future prospects.
• The transactions were made pursuant to a Securities Purchase Agreement and the Issuer's 2021 Equity Incentive Plan, suggesting a structured and planned investment.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Stan Smith's indirect beneficial ownership through The Stan V. Smith Trust Dated 1993 and three family trusts (Blake Sarai Teitei Smith IL Unif Trns Min Act, Gage Quentin Smith IL Unif Trns Min Act, Travis Deo Zai Zai Smith IL Unif Trns Min Act) represents transactions with entities related to the reporting person.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive signal, potentially boosting investor confidence in MAIA Biotechnology, Inc.'s prospects.

Next Steps

• The acquired stock options will become exercisable on June 22, 2026.
• The acquired stock options will expire on December 22, 2028.

Key Dates

Recommendation

The significant purchase of common stock and stock options by a director, Stan Smith, indicates strong insider confidence in MAIA Biotechnology's future. This type of insider buying often precedes positive company developments or reflects a belief that the stock is undervalued, making it a compelling 'buy' signal for investors.

Keywords

MAIA Biotechnology, MAIA, Stan Smith, Insider Trading, Form 4, Stock Purchase, Stock Options, Director, Equity Incentive Plan, Biotechnology